2858
Helvetica Chimica Acta Vol. 87 (2004)
CDCl3): 0.59 0.67 (m, 6 H); 0.96 (t, J 8.1, 9 H); 1.17 (dd, J 7.0, 4.5, 1H); 2.04 2.06 ( m, 1H); 4.24 ( m, 2 H).
13C-NMR (MHz, CDCl3): 2.0 (t); 7.2 (q); 13.3 (s); 15.6 (t); 21.9 (t); 68.2 (t); 178.8 (s). MS: 183 (85,
[M À C2H5] ), 139 (30), 111 (100), 83 (42), 59 (27), 53 (36). HR-MS: 183.0850 (C9H15O2Si ; calc. 183.0841).
rel-(1R,5S,6R)-6-Phenyl-1-(triethylsilyl)-3-oxabicyclo[3.1.0]hexan-2-one (9b). After FC (SiO2, pentane/
AcOEt 97:3), yield 9% with [Rh2{(S)-nttl}4] and 10% with [Rh2{(S)-bpttl}4] (Table 3). Colorless oil. IR (film):
2953m, 2874m, 1713s, 1189s, 1051s, 966s. 1H-NMR (300 MHz, CDCl3): 0.31 0.52 ( m, 6 H); 0.88 (t, J 7.9, 9 H);
2.56 (d, J 4.5, 1H); 2.75 ( t, J 4.0, 1H); 4.40 4.50 ( m, 2 H); 7.30 7.40 (m, 5 H). 13C-NMR (75 MHz,
CDCl3): 2.9 (t); 7.3 (q); 23.6 (s); 25.7 (d); 33.3 (d); 68.3 (t); 127.7 (d); 128.4 (d); 129.2 (d); 135.2 (s); 178.4 (s).
MS: 259 (100, [M À C2H5] ), 157 (43), 129 (48), 115 (14), 87 (41), 59 (26). HR-MS: 259.1143 (C9H15O2Si ; calc.
259.1154).
rel-(1S,5R)-5-Methyl-1-(triethylsilyl)-3-oxabicyclo[3.1.0]hexan-2-one (9c). After FC (SiO2, pentane/
AcOEt 97 :3), yield 20% with [Rh2{(S)-nttl}4] (Table 3). Colorless oil. Enantiomer separation by GC (b-
Dex, 5 min at 1208, then 18/min to 1808, 10 min at 1808): tR 27.5 (minor) and 27.7 (major). IR: 2954m, 2879m,
1
1750s, 1188s, 1056s, 1006s. H-NMR (300 MHz, CDCl3): 0.68 0.76 (m, 6 H); 0.99 (t, J 7.5, 9 H); 1.09 (d, J
4.2, 1H); 1.16 ( d, J 3.9, 1H); 1.36 ( s, 3 H); 3.94 (d, J 8.8, 1H); 4.20 ( d, J 8.8, 1H). 13C-NMR (75 MHz,
CDCl3): 2.5 (t); 7.3 (q); 16.8 (q); 22.9 (t); 30.0 (s); 72.2 (t); 113.9 (s); 179.4 (s). MS: 197 (100, [M À C2H5] ), 125
(92), 115 (36), 103 (24), 97 (54), 87 (52). HR-MS: 197.1004 (C12H22O2Si ; calc. 197.0998).
cis-4-(1-Methylethenyl)-3-(triethylsilyl)oxetan-2-one (11). After FC (SiO2, pentane/AcOEt 97:3), yield
1
18% with [Rh2{(S)-nttl}4]. IR (film): 2956m, 2874m, 1807s, 1255w, 1111s, 1008s. H-NMR (300 MHz, CDCl3):
0.67 0.76 (m, 6 H); 0.98 (t, J 8.1, 9 H); 1.79 (s, 3 H); 3.55 (dd, J 6.4, 2.5, 1H); 4.88 ( d, J 6.4, 1H); 5.08
(s, 1H); 5.26 ( s, 1 H). 13C-NMR (75 MHz, CDCl3): 3.5 (t); 7.2 (q); 19.1 (d); 44.6 (q); 73.3 (d); 113.0 (t); 140.2
(s); 170.0 (s). MS: 226 (3, M ), 198 (17), 197 (100), 125 (54), 103 (38), 75 (54). HR-MS: 226.138750
(C12H22O2Si ; calc. 226.1389).
(1S,5R,6R)-6-Ethyl-1-(triethylsilyl)-3-oxabicyclo[3.1.0]hexan-2-one (9d). After FC (SiO2, pentane/AcOEt
97:3), yield 76% with [Rh2{(S)-nttl}4], 38% ee (determined after desilylation to 10d). For abs. configuration,
1
see below. Colorless oil. IR (film): 2952m, 2873m, 1745s, 1197w, 1070m, 1000m. H-NMR (500 MHz, CDCl3):
0.64 (q, J 7.7, 6 H); 0.96 (t, J 7.7, 9 H); 1.04 (t, J 7.2, 3 H); 1.26 1.55 (m, 3 H); 2.08 (t, J 5.6, 1H); 4.13
(d, J 9.6, 1H); 4.29 ( dd, J 9.6, 5.5, 1H). 13C-NMR (MHz, CDCl3): 2.1( t); 7.2 (q); 13.3 (q); 17.0 (t); 19.4 (s);
27.1( d); 27.3 (d); 65.1( t); 177.1 (s). MS: 211 (100, [M À C2H5] ), 115 (16), 109 (15), 103 (69), 81 (25), 75 (46).
HR-MS: 211.1158 (C11H19O2Si ; calc. 211.1154).
3.4. Desilylation of 1-(Triethylsilyl)-3-oxabicyclo[3.1.0]hexan-2-ones 9a,d: General Procedure. At r.t., 1m
Bu4NF in THF (1ml) was added dropwise to the appropriate oxabicyclohexanone (0.56 mmol). After stirring
for 2 4 h, H2O (2.0 ml) was added, the mixture extracted with CH2Cl2, the org. layer dried (MgSO4) and
evaporated, and the residue purified by FC.
(1R,5S)-3-Oxabicyclo[3.1.0]hexan-2-one (10a). FC (SiO2, pentane/AcOEt 96 :4) afforded 12 mg (36%) of
10a. Colorless oil. Enantiomer separation by GC (Lipodex E, 10 min at 1008, then 18/min to 1508, 10 min at
1508). tR 27.6 ((1R,5S), major) and 29.8 ((1S,5R), minor); for abs. configuration, see 3.4. 1H-NMR (300 MHz,
CDCl3): 0.85 0.88 (m, 1H); 1.22 1.30 ( m, 1H); 2.03 2.10 ( m, 1H); 2.20 2.27 ( m, 1H); 4.22 ( d, J 9.2 Hz,
1H); 4.32 4.37 ( m, 1 H).
(1R,5S,6R)-6-Ethyl-3-oxabicyclo[3.1.0]hexan-2-one (10d). FC (SiO2, pentane/AcOEt 96 :4) afforded
12 mg (37%) of 10d. Colorless oil. Enantiomer separation by GC (Lipodex E, 5 min 1208, 18/min to 1608, 10 min
1608): tR 17.4 ((1S,5R,6S), minor) and 18.1 ((1R,5S,6R), major); for abs. configuration, see 3.4. [a]2D0 26.3 (c
0.24, EtOH, for 28% ee). IR (film): 2965m, 2876w, 1756s, 1173w, 1058s, 979s. 1H-NMR (300 MHz, CDCl3): 1.07
(t, J 6.8, 3 H); 1.40 1.43 (m, 3 H); 2.18 2.29 (m, 2 H); 4.15 (d, J 9.9, 1H); 4.41 ( dd, J 9.8, 5.3, 1H).
13C-NMR (75 MHz, CDCl3): 13.3 (q); 16.3 (t); 22.5 (d); 22.7 (d); 23.9 (d); 66.0 (t); 175.1 (s). MS: 126 (3, M ),
111 (9), 97 (15), 85 (100), 67 (84), 55 (46). HR-MS: 126.0688 (C7H10O2 ; calc. 126.0680).
3.4. Absolute Configuration of 10a,d. Optically active 3-oxabicyclo[3.1.0]hexan-2-ones 10a,d of known
absolute configuration were synthesized via intramolecular cyclopropanation of 7a and 7d, respectively, in the
presence of [Rh2{(S)-mepy}4] according to the General Procedure described in 3.3.
(1R,5S)-3-Oxabicyclo[3.1.0]hexan-2-one (10a). FC (SiO2, pentane/AcOEt 95 :5) afforded 61mg (37%) of
10a with 89% ee. Enantiomer separation by GC (Lipodex E, 10 min at 1008, then 18/min to 1508, 10 min at 1508):
tR 27.0 ((1R,5S), major) and 29.9 ((1S,5R), minor).
(1R,5S,6R)-6-Ethyl-3-oxabicyclo[3.1.0]hexan-2-one (10d). FC (SiO2, pentane/AcOEt 95 :5) gave 46 mg
(38%) of 10d with 97% ee. Enantiomer separation by GC (Lipodex E, 5 min at 1208, then 18/min to 1608, 10 min
at 1608): tR 17.3 ((1S,5R,6S), minor) and 17.9 ((1R,5S,6R), major).